Intravenous immunoglobulin iherapy in autoimmune mucocutaneous blistering diseases: A review of the evidence for its efficacy and safety

被引：27

作者：

Gürcan H.M. ^{[1
]}

Jeph S. ^{[1
]}

Ahmed R.A. ^{[1
]}

机构：

[1] Center for Blistering Diseases, New England Baptist Hospital, Boston, MA 02120

来源：

American Journal of Clinical Dermatology | 2010年 / 11卷 / 5期

关键词：

Kawasaki Disease; Pemphigus; Immune Thrombocytopenic Purpura; Bullous Pemphigoid; IVIg Therapy;

D O I：

10.2165/11533290-000000000-00000

中图分类号：

学科分类号：

摘要：

Intravenous immunoglobulin (IVIg) is a biologic agent that is being increasingly used in the treatment of autoimmune and chronic inflammatory disorders. It is approved by the US FDA for the treatment of primary immunodeficiencies, immune thrombocytopenic purpura, Kawasaki disease, bone marrow transplantation in patients aged over 20 years, chronic B-cell lymphocytic leukemia, and pediatric AIDS. IVIg has been used off-label for several diseases, clinical symptoms and syndromes. Our aim was to determine if there is evidence to support the efficacy of IVIg therapy in autoimmune mucocutaneous blistering diseases (AMBDs). We searched the PubMed database for studies on pemphigus and pemphigoid using the following criteria: (i) English language; (ii) minimum of five patients; (iii) diagnosis based on histology and immunopathology; and (iv) statistical analysis of data for comparison of efficacy provided. We evaluated the data and present information on the number of participants in each study, pre-IVIg therapy, indications for the use of IVIg, IVIg protocol (dose and interval) used, concomitant therapies, clinical outcome, follow-up period, and serologic studies. The quality of the evidence presented in this review is at Level A according to the UK National Health Service criteria. Twenty-three studies that were published between May 1999 and April 2010 were identified. One randomized controlled trial was found and all other studies were case series. Data on 260 patients treated with IVIg were analyzed: 191 patients with pemphigus and 69 patients with pemphigoid. Overall, 245 patients showed improvement with IVIg therapy. IVIg demonstrated a corticosteroid-sparing effect. In the studies presented, the incidence of serious adverse effects was not significant. The best available evidence in the literature indicates that IVIg is efficacious and has a good safety profile in the treatment of AMBDs. © 2010 Adis Data Information BV. All rights reserved.

引用

页码：315 / 326

页数：11

共 44 条

[1]

Evidence-based medicine: A new approach to teaching the practice of medicine. Evidence-Based Medicine Working Group, JAMA, 268, 17, pp. 2420-2425, (1992)

[2]

Guyatt G.H., Sackett D.L., Cook D.J., Users' guides to the medical literature: II. How to use an article about therapy or prevention. A: Are the results of the study valid? Evidence-based medicine working group, JAMA, 270, 21, pp. 2598-2601, (1993)

[3]

Guyatt G.H., Sackett D.L., Cook D.J., Users' guides to the medical literature: II. How to use an article about therapy or prevention. B: What were the results and will they help me in caring for my patients? Evidence-based medicine working group, JAMA, 271, 1, pp. 59-63, (1994)

[4]

Guyatt G.H., Rennie D., Users' guides to the medical literature, JAMA, 270, 17, pp. 2096-2097, (1993)

[5]

Ahmed A.R., Use of intravenous immunoglobulin therapy in autoimmune blistering diseases, Int Immunopharmacol, 6, 4, pp. 557-578, (2006)

[6]

Ahmed A.R., Dahl M.V., Consensus statement on the use of intravenous immunoglobulin therapy in the treatment of autoimmune mucocutaneous blistering diseases, Arch Dermatol, 139, 8, pp. 1051-1059, (2003)

[7]

Orange J.S., Hossny E.M., Weiler C.R., Et al., Use of intravenous immunoglobulin in human disease: A review of evidence by members of the Primary Immunodeficiency Committee of the American Academy of Allergy, Asthma and Immunology, J Allergy Clin Immunol, 117, (2006)

[8]

Amagai M., Ikeda S., Shimizu H., Et al., A randomized double-blind trial of intravenous immunoglobulin for pemphigus, J AmAcad Dermatol, 60, 4, pp. 595-603, (2009)

[9]

Harman K.E., Black M.M., High-dose intravenous immune globulin for the treatment of autoimmune blistering diseases: An evaluation of its use in 14 cases, Br J Dermatol, 140, 5, pp. 865-874, (1999)

[10]

Ahmed A.R., Intravenous immunoglobulin therapy in the treatment of patients with pemphigus vulgaris unresponsive to conventional immunosuppressive treatment, J Am Acad Dermatol, 45, 5, pp. 679-690, (2001)

← 1 2 3 4 5 →